{"name":"Suzhou Abogen Biosciences Co., Ltd.","slug":"suzhou-abogen-biosciences-co-ltd","ticker":"","exchange":"","domain":"suzhouabogen.com","description":"Suzhou Abogen Biosciences Co., Ltd. is a biotechnology company focused on the research and development of innovative therapies. The company has a pipeline of six drug candidates, with several in early-stage clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ABO1009-DP","genericName":"ABO1009-DP","slug":"abo1009-dp","indication":"Other","status":"phase_1"},{"name":"ABO2011 Injection","genericName":"ABO2011 Injection","slug":"abo2011-injection","indication":"Other","status":"phase_1"},{"name":"ABO-CoV.617.2","genericName":"ABO-CoV.617.2","slug":"abo-cov-617-2","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ABO1105","genericName":"ABO1105","slug":"abo1105","indication":"Metastatic non-small cell lung cancer","status":"phase_2"},{"name":"ABO1020","genericName":"ABO1020","slug":"abo1020","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ABO1108","genericName":"ABO1108","slug":"abo1108","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"ABO1009-DP","genericName":"ABO1009-DP","slug":"abo1009-dp","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABO1105","genericName":"ABO1105","slug":"abo1105","phase":"phase_2","mechanism":"ABO1105 is a small molecule that targets the PI3K/AKT/mTOR pathway.","indications":["Metastatic non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"ABO1108","genericName":"ABO1108","slug":"abo1108","phase":"phase_2","mechanism":"ABO1108 is a small molecule targeting the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ABO2011 Injection","genericName":"ABO2011 Injection","slug":"abo2011-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABO-CoV.617.2","genericName":"ABO-CoV.617.2","slug":"abo-cov-617-2","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABO1020","genericName":"ABO1020","slug":"abo1020","phase":"phase_2","mechanism":"ABO1020 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBOaW1kZlkwWDRQVHlQd2VaWm9VSEwwU0pMUl9rQU9UWmdmalhCZHlvQ1BNSUtKOVJSc0s0TkNsajd0TUF0WkhDc1B1Vld6MEE2QU5zZ282UzhpMG92R0c4aE9EOWtBc3k3T3c?oc=5","date":"2025-09-04","type":"pipeline","source":"Straits Research","summary":"RNA Therapeutics Market Size, Top Share | Industry Report, 2034 - Straits Research","headline":"RNA Therapeutics Market Size, Top Share | Industry Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPMlBCOFhSQUFLVm5hYzBiSFpJcGdVMVAtVl9mbWZPVVF2Z0k2UFBoYURrSzk0VW9SdXYzMHBCRjFyel82c3BwZzZjYnpFRG5UMmFLeGdiQWtXS2tlc0NzY24yQkU1OTNSWE0teW5iM2ljanlQSVdsMnBQUGdvZlhlNWNrcVRHWkJLX1QzYXRtUVp4Z2VnX3Z5R3k3Z0FRN3lxTkcxdkUwQ0dFRFNhMjREWE9EYXJ1dnBzNXZtRnhONlRKS3M2?oc=5","date":"2024-04-19","type":"pipeline","source":"Reuters","summary":"Focus: China's drugmakers can't sell mRNA shots but haven't quit yet - Reuters","headline":"Focus: China's drugmakers can't sell mRNA shots but haven't quit yet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxNZVJ4eFhSWnBncXZ4U0h6aWk1UlA2anBRNmV1OGJ6QjNBTHJGMlRFVGZqMm56UDg2X2xVY1VOaXBUcWhZWGcxalJVZVpSV3F5bXhPTWY1ZWRlM1c5RERrVGtBcmdVZDRsOENmZk1LOWt6REFUbjFQTHVycDhfX1JaQTR6cW1lWXZFZjc2RDd0QVJTM09OQ0ZJc05lUkFPVkF3VVFWazM1b1JQbmFKV1YyNmZiOVEwbS1LOW96bEJZMWZUZm1ITTdxdkNzMk56VXByWDBrWEpzNW1EalE?oc=5","date":"2022-09-30","type":"regulatory","source":"Reuters","summary":"A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia - Reuters","headline":"A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNd2sxUlBONHdpYl9tanpWVHVycXlJZXZXemxvVXVqeGxaSkxwVTYxVnVXWHIzbjB0eUNkd29pTDVheFd2MkhPRjlHU0hnVU85NWFRUmttRHlMcGk4RzBSN3hfNWVXVTRGRExDZHozNW8tUHJOR2FjRmNtWWdIak0wWmtrRWdBa1B2YmZSck96SUVCYXFNWEZGeG81STZmR3JKUDNsMHZGTlhzVS1CMU5QOXJEbjV1V0tlazFBVWpuQmZXZUQzaHpqTzlZdF9jOHFlcHY3aTJJVzI1akNhaGc?oc=5","date":"2022-03-01","type":"pipeline","source":"Reuters","summary":"China perseveres with mRNA COVID shot development amid Omicron, commercial uncertainty - Reuters","headline":"China perseveres with mRNA COVID shot development amid Omicron, commercial uncertainty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNTGdBakJTaTJWY1dxazh3SGZNZmlMU1lyR3hBUWxHNHBwWERFcHdkUGJha1N1aHp1RDFoM25GdDJMUk9yY09FUmRSYlNKMHdhTHQyUkNYYzBMTC1fUV9abVZWb2FVaWhnQThrNlhTbEEtcVJ1SnFhTk5wUVl0ZzJxdW4xdFI0aW41bnRuZXoxaGhhc3RFbjFHbzU3NDhlTHRzcmliOGRsNHZGVVZvVmc?oc=5","date":"2022-02-21","type":"trial","source":"The Kathmandu Post","summary":"Phase III trials of Chinese mRNA Covid vaccine in Nepal cancelled - The Kathmandu Post","headline":"Phase III trials of Chinese mRNA Covid vaccine in Nepal cancelled","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQTDI5a1FuTEFiaVZEcm1YMEdSWUY2MG9aX0VJN1d0Rmg0TEs2NDdSOEd1ZWFOZWdCNkVZVlVYMkwtejFRSWhRR1dnalN5QTlVR0U2RzMyWTdrRWYtTm5VZ3NHZE16WkVEbjY2d2JDUHY3X0ZobjNXbDV3N0lZUGM1MENmUlA5MmthV3NsdmhXVGMycVFVYmQ3cTln?oc=5","date":"2021-09-14","type":"trial","source":"The Kathmandu Post","summary":"Two Covid-19 vaccines set to start trials in Nepal - The Kathmandu Post","headline":"Two Covid-19 vaccines set to start trials in Nepal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNR2RIOHRPZ2RfTy01OWg5bEJnNzMxbGV3RERJSG1Ka0lCUE5DRWtjZHg5d19NRWp3cjFBbnFMQWVFS0hWTllXWmZnR2hCRnkwa19qR09mVzN5MjNaZlF5Q1EwcWZDM2JtdEZ5UGFOSk41U01od2psdVhrbVBGZFlEaWlNaVZvV2NONFJ0ZHVoX2pISWZ3eWlOUG9peERBZjYyRkF0c0lMOVB2TjJkT0N2M19DbmdRS0FjYTFOMzRDMnNBYktkVHBPWlZoaWo2Wk0?oc=5","date":"2021-08-19","type":"pipeline","source":"Reuters","summary":"China's mRNA vaccine technology firm Abogen raises over $700 mln - Reuters","headline":"China's mRNA vaccine technology firm Abogen raises over $700 mln","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_1":3,"phase_2":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}